What is SpacePharma?
SpacePharma stands as a pioneering Swiss-Israeli biotechnology firm, distinguished by its singular focus on executing scientific experiments within the unique environment of microgravity. It holds the distinction of being the first fully private, commercially oriented entity established with the explicit objective of advancing pharmaceutical research and development (R&D) and manufacturing capabilities in space. Founded by Yossi Yamin, a former Commander of an Israeli Satellite Unit in the IDF, the company operates globally with offices in Herzliya, Israel; Courgenay, Switzerland; and Palo Alto, California, complemented by a dedicated Space Life Sciences Lab in Exploration Park, Florida, USA. This strategic positioning allows SpacePharma to leverage international expertise and infrastructure for its ambitious space-based R&D initiatives.
How much funding has SpacePharma raised?
SpacePharma has raised a total of $2.1M across 1 funding round:
Grant
$2.1M
Grant (2024): $2.1M with participation from European Union
Key Investors in SpacePharma
European Union
The European Union, a significant governmental body, often provides grants and funding to support scientific research and development, particularly in areas aligned with its strategic goals for innovation and societal well-being.
What's next for SpacePharma?
The recent major strategic investment in SpacePharma signals a robust commitment to scaling its operations and accelerating its R&D pipeline. This influx of capital is anticipated to fuel further advancements in space-based pharmaceutical manufacturing and experimentation, potentially solidifying its leadership in this niche yet critical industry. The company's focus on microgravity research positions it to unlock novel therapeutic discoveries and manufacturing processes that are unattainable on Earth, paving the way for future breakthroughs in medicine and biotechnology.
See full SpacePharma company page
